Clinical studies in brain cancer

Several clinical studies of the novel antisense drug trabedersen (AP 12009) for the treatment of high-grade or malignant glioma (the most aggressive form of primary central nervous system tumor) have already been completed. Before administration in humans, the safety of trabedersen was investigated in animal studies. Three Phase I/II studies were carried out in adult patients, in which an independent committee of experts rated trabedersen therapy as safe. A larger Phase IIb study with trabedersen confirmed the good safety profile and demonstrated very encouraging signs of efficacy compared to standard chemotherapy in high-grade glioma patients.